ArticleCancer medicine2026
Multi-Omics Analysis of TYMS as a Prognostic Biomarker and Therapeutic Target for Lung Adenocarcinoma.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD) is a predominant form of lung cancer with poor prognosis due to early diagnosis challenges and treatment resistance. Thymidylate synthetase (TYMS), a key enzyme in DNA synthesis, has been associated with poor prognosis in multiple cancers, yet its multi-omics characteristics in LUAD remain systematically uncharacterized. This study focuses specifically on LUAD, integrating transcriptomic, proteomic, and genomic data to elucidate TYMS expression patterns, prognostic value, immune microenvironment interactions, and therapeutic potential. Using data from The Cancer Genome Atlas (TCGA), the Clinical Proteomic Tumour Analysis Consortium (CPTAC), the Genome-Tissue Expression Project (GTEx), the Gene Expression Profile Interaction Analysis (GEPIA2), etc., we conducted comprehensive bioinformatics analyses of TYMS in LUAD. TYMS showed significant overexpression at both mRNA and protein levels in LUAD tissue. High TYMS expression correlated with earlier tumour staging, higher histological grade, and poor prognosis. Functional enrichment analysis revealed TYMS involvement in p53/Rb and mammalian Target of Rapamycin (mTOR) signalling pathways. TYMS expression was associated with immune cell infiltration, showing negative correlation with B-cell activity and positive correlation with neutrophil infiltration, as well as significant association with Cytotoxic T Lymphocyte-Associated Protein 4 (CTLA4), Programmed Death-1 (PDCD1, PD-1), and Interleukin-6 (IL-6). Somatic copy number variation (SCNA) analysis indicated that TYMS amplification was linked to poor prognosis and enriched in the folate metabolism pathways. Drug sensitivity analysis demonstrated that high TYMS expression positively correlated with sensitivity to Afatinib and Gefitinib, but negatively correlated with Methotrexate and Vorinostat. In conclusion, TYMS is upregulated in LUAD and may serve as an independent prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.